Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Edison will be hosting a call to discuss new CNS drugs including esketamine, SAGE-547, and SAGE-217.

Ticker(s): SAGE, AGN, JNJ

Who's the expert?

Name: Dr Michael Thase - MD

Institution: Private Practice & UPenn

  • Professor of Psychiatry at the Perelman School of Medicine of the University of Pennsylvania.
  • Leading figure in the pharmacotherapy of mood disorders. Research focuses on the assessment and treatment of mood disorders, including studies of the differential therapeutics of both depression and bipolar affective disorder.
  • Has authored or co-authored more than 500 scientific articles and book chapters, as well as 15 books.

Interview Questions
Q1.

Please describe your background and clinical practice. How do you currently treat patients with MDD and PPD?

Added By: joe_mccann
Q2.

What is the potential for esketamine in patients with Major Depressive Disorder.

Added By: joe_mccann
Q3.

How many post-partum depression patients would be severe enough to be willing to sit through a 60 hour infusion of SAGE-547?

Added By: joe_mccann
Q4.

Do you think SAGE-217 will have a different profile than classes of drugs with a similar mechanism, such as benzodiazepines.

Added By: joe_mccann
Q5.

What are the  chemical or pharmacokinetic differences between SAGE-547 and other synthetic formulations of allopregnanolone (e.g. ganoxolone)?  Would these differences be expected to have any clinical impact?

Added By: festina_lente
Q6.

Among the rapid acting antidepressant candidates in late stage clinical trials, can you summarize the clinical data comparing ketamine and derivatives like esketamine to glutamate NR2B modulators such as GLYX-13?  Which group might be expected to have greater safety, efficacy, favorable pharmacokinetic properties or clinical utility?

Added By: festina_lente
Q7.

Do you expect that the advantages of SAGE 217 over SAGE 547 and ganoxolone publicized in pre-clinical studies (rodent plasma to brain ratio, potency of GABA modulation, less off target activity) will manifest in any difference in clinical efficacy/safety? In other words, assuming eventual regulatory approval for this class of drugs, in your opinion, how likely are clinicians to choose SAGE 217 over SAGE 547 or ganoxolone (in psychiatric indications)?

Added By: festina_lente
Q8.

Given the linkages between postpartum depression and bipolar disorder, would you expect that the neurosteroid antidepressants would also have efficacy in bipolar depression? 

Added By: festina_lente
Q9.

Can you comment on your opinion of the psychomimetic side effect profile of esketamine?  It seems mechanistically unlikely that an enantiomer of ketamine would not have at least some of the psychomimetic and dissociative qualities of racemic ketamine.  In other antidepressants, enantiomeric formulations have been criticized as being "me-too" drugs, introduced as patent life extenders rather than novel clinical formulations. 

Added By: festina_lente

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.